In breast cancer cells, a high level of miR-378* induces the metabolic shift from an oxidative to a glycolytic bioenergetics pathway by inhibiting the expression of two PGC-1β partners, ERRγ (estrogen-related receptor gamma) and GABPA (GA binding protein transcription factor, alpha subunit). The gene discussed is ESRRG; the disease is breast cancer.